Dr Reddy's Q2 Results: Revenue Rises 17% To Rs 8,106 Crore

Dr Reddy’s Laboratories Ltd. reported its Q2 FY25 results, with a notable revenue increase of 16.5%, reaching Rs 8,016.2 crore, surpassing estimates. However, the company saw a 9.5% decline in profit, which stood at Rs 1,342 crore compared to Rs 1,482 crore in the previous year. EBITDA rose 3.5% to Rs 2,054.5 crore, though margins narrowed to 25.6% from 29%. The company has reiterated its FY25 guidance, with R&D expenses expected to remain at around 8.5%. North America revenue saw a significant 17% growth YoY, while Europe also experienced a 9% increase. Dr. Reddy’s is preparing to launch a key biosimilar in 2027. Watch the exclusive conversation with M.V. Ramana, CEO - India & Emerging Markets, Dr. Reddy's, on Q2 results and future growth plans, in conversation with Business Today TV Managing Editor Siddharth Zarabi.